The Company’s first product that implemented the Biomatrix Particulate Technology, SPRYNG™ with OsteoCushion™ Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles; SPRYNG microparticles perform in the joint as wet, slippery micro-cushions used in the management of lameness and other joint related afflictions, such as osteoarthritis. https://www.petvivo.com/news-1/petviv... “Our biocompatible particulate technology and the claims to be issued in this patent application provides extremely comprehensive coverage. This patent increases the scope of our patent claims thereby expanding our competitive advantage in the commercialization of products used in the treatment of humans and companion animals,” stated PetVivo Chief Executive Officer, John Lai. https://www.petvivo.com/abouthttps://... https://www.petvivocares.org/ ****** The views expressed in Markets Hunter's content, productions, or other investor relations materials and presentations may be subject to change. Neither Markets Hunter nor any of its data or content providers shall be held responsible for any errors or delays in the content, or for any actions taken based on the information provided. All data and information is intended to be used for informational or entertainment purposes only. On occasion, we enter into contracts with third parties or publicly traded companies and receive financial remuneration in exchange for disseminating information and opinions regarding the company and the stock market such as this video. Markets Hunter is not a licensed broker-dealer or registered investment advisor. The content and productions of Markets Hunter are sourced from reliable data sources, though accuracy and completeness are not guaranteed. Consequently, the information should not be seen as tailored advice to any individual investor's specific needs. Markets Hunter.com is devoted to furnishing our readers with beneficial insights into publicly traded companies.